Analysis of durability of response to thalidomide treatment for relapsed myeloma patients

被引：3
|
作者：
Myers, B [1 ]
Dolan, G [1 ]
机构：
[1] Univ Nottingham Hosp, Queens Med Ctr, Dept Clin & Lab Haematol, Nottingham NG7 2UH, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 118卷 / 01期
关键词：
thalidomide; myeloma; therapy; duration;
D O I：
10.1046/j.1365-2141.2002.03576_4.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：347 / 347
页数：1
相关论文
共 50 条
  • [31] LENALIDOMIDE IN RELAPSED REFRACTORY MYELOMA PATIENTS: IMPACT OF PREVIOUS RESPONSE TO BORTEZOMIB AND THALIDOMIDE ON TREATMENT EFFICACY. RESULTS OF A MEDICAL NEED PROGRAM IN BELGIUM
    Delforge, M.
    Michiels, A.
    Doyen, C.
    Kentos, A.
    Van Droogenbroeck, J.
    Offner, F.
    Bries, G.
    Demuynck, H.
    Vekemans, M. C.
    Meuleman, N.
    Mineur, P.
    Ravoet, C.
    Depryck, B.
    Van de Velde, A.
    Pierre, P.
    Wu, K. L.
    Schots, R.
    ACTA CLINICA BELGICA, 2011, 66 (05) : 371 - 375
  • [32] LOW-DOSE THALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Kohei, K. O.
    Ando, S.
    Hasino, S.
    Huse, H.
    Morita, R.
    Takahata, M.
    Onozawa, M.
    Kahata, K.
    Kondo, T.
    Ota, S.
    Kawamura, T.
    Kurosawa, M.
    Aikawa, K.
    Ogawa, T.
    Suzuki, S.
    Takahashi, S.
    Izumiyama, K.
    Iwasaki, H.
    Maemori, M.
    Sakai, H.
    Asaka, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 619 - 620
  • [33] Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Gleason, Charise
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Valla, Kelly
    Heffner, Leonard T.
    Bisht, Aditya Singh
    Manubolu, Sanjay
    Watson, Melanie
    Boise, Lawrence H.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
  • [34] Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma.
    Tosi, P
    Ronconi, S
    Zamagni, E
    Cellini, C
    Tura, S
    Cavo, M
    BLOOD, 2000, 96 (11) : 296B - 296B
  • [35] Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
    Heinz Ludwig
    Wolfram Poenisch
    Stefan Knop
    Alexander Egle
    Martin Schreder
    Daniel Lechner
    Roman Hajek
    Eberhard Gunsilius
    Karl Jochen Krenosz
    Andreas Petzer
    Katja Weisel
    Dietger Niederwieser
    Hermann Einsele
    Wolfgang Willenbacher
    Thomas Melchardt
    Richard Greil
    Niklas Zojer
    British Journal of Cancer, 2019, 121 : 751 - 757
  • [36] Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial
    Ludwig, Heinz
    Lechner, Daniel
    Gunsilius, Eberhard
    Fridrik, Michael
    Petzer, Andreas
    Kuehr, Thomas
    Knop, Stefan
    Schreder, Martin
    Weisel, Katja
    Rauch, Elisabeth
    Poenisch, Wolfram
    Greil, Richard
    Zojer, Niklas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E75 - E75
  • [37] Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Palumbo, Antonio
    Ambrosini, Maria Teresa
    Benevolo, Giulia
    Pregno, Patrizia
    Pescosta, Norbert
    Callea, Vincenzo
    Cangialosi, Clotilde
    Caravita, Tommaso
    Morabito, Fortunato
    Musto, Pellegrino
    Bringhen, Sara
    Falco, Patrizia
    Avonto, Ilaria
    Cavallo, Federica
    Boccadoro, Mario
    BLOOD, 2007, 109 (07) : 2767 - 2772
  • [38] Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
    Badros, AZ
    Siegel, E
    Bodenner, D
    Zangari, M
    Zeldis, J
    Barlogie, B
    Tricot, G
    AMERICAN JOURNAL OF MEDICINE, 2002, 112 (05): : 412 - 413
  • [39] Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD).
    Srkalovic, G
    Karam, MA
    Trebisky, BM
    Hussein, MA
    BLOOD, 2000, 96 (11) : 294B - 295B
  • [40] Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
    Juliusson, G
    Celsing, F
    Turesson, I
    Lenhoff, S
    Adriansson, M
    Malm, C
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) : 89 - 96
12345